StereotaxisSTXS
STXS
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
545% more call options, than puts
Call options by funds: $284K | Put options by funds: $44K
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
17% more funds holding
Funds holding: 71 [Q2] → 83 (+12) [Q3]
13% more capital invested
Capital invested by funds: $73.2M [Q2] → $82.4M (+$9.2M) [Q3]
0.97% less ownership
Funds ownership: 48.69% [Q2] → 47.72% (-0.97%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for STXS.
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.
Positive
Zacks Investment Research
1 month ago
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
Neutral
GlobeNewsWire
1 month ago
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA).
Neutral
GlobeNewsWire
1 month ago
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL.
Positive
Seeking Alpha
1 month ago
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.
Positive
Zacks Investment Research
1 month ago
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
Neutral
GlobeNewsWire
1 month ago
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference.
Neutral
GlobeNewsWire
1 month ago
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of the Genesis RMN ® System by China's National Medical Products Administration (NMPA).
Neutral
GlobeNewsWire
2 months ago
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
Neutral
Seeking Alpha
2 months ago
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.
Charts implemented using Lightweight Charts™